“淘宝之父”孙彤宇押注成功，觅瑞集团港交所上市市值超80亿

Core Viewpoint - MIRXES-B, a company focused on RNA technology, successfully listed on the Hong Kong Stock Exchange on May 23, with an initial price of 23.3 HKD, experiencing a significant opening increase of 24.89% to reach 29 HKD, and closing at 29.9 HKD, resulting in a total market capitalization of 82.62 billion HKD [1][2]. Company Overview - MIRXES-B was founded in 2014 in Singapore by Zhu Xingfen, Zhou Lihan, and Zou Ruiyang, focusing on developing blood-based miRNA testing kits for early disease detection globally [3][4]. - The company's core product, GASTROClearTM, is the first and only regulatory-approved molecular IVD product for gastric cancer screening, characterized by its non-invasive, rapid, and convenient features [3][4]. Financial Performance - The company reported revenues of 17.76 million USD, 24.18 million USD, and 20.28 million USD for the years 2022, 2023, and 2024, respectively, with gross profits of 9.33 million USD, 13.58 million USD, and 8.89 million USD during the same period [5]. - However, the company also faced increasing losses, reported at 56.20 million USD, 69.57 million USD, and 92.21 million USD for the same years [5]. Investment and Funding - The IPO attracted significant cornerstone investors, including Beijing Xunrui and Evergreen Gate, who collectively subscribed to shares worth 57.92 million USD, with Beijing Xunrui investing 50 million USD and Evergreen Gate investing 7.92 million USD [3]. - Notably, Sun Tongyu, former president of Taobao, played a crucial role in the company's funding, having invested 4 million SGD (approximately 2.8 million USD) in 2016 and later participating in a 30 million USD Series B funding round [4]. - Following the IPO, Sun Tongyu's stake in MIRXES-B is valued at approximately 1.839 billion HKD, reflecting a 7x return on investment [4].